Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RIFAREN 300 CAPSULE 300 mg - HSA Drug Approval Details

Approvals/HSA/RIFAREN 300 CAPSULE 300 mg

Approved

STANDARD

RIFAREN 300 CAPSULE 300 mg

Unknown🇸🇬 Health Sciences Authority

Approval Date: Jan 13, 2026
Approval ID: 7c2fa7faefa0fbbb
Company: Unknown
Type: Standard

Approval Details

Approval Id: 7c2fa7faefa0fbbb
Drug Name: RIFAREN 300 CAPSULE 300 mg

Active Ingredients

RIFAMPICIN

300 mg

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jan 13, 2026

Approval ID

7c2fa7faefa0fbbb

Type

Standard

Back to HSA Approvals